IN8bio’s (INAB) “Buy” Rating Reaffirmed at HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $8.00 target price on the stock.

IN8bio Stock Performance

NASDAQ:INAB opened at $0.30 on Tuesday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The firm’s fifty day simple moving average is $0.30 and its 200 day simple moving average is $0.64. The stock has a market cap of $22.02 million, a P/E ratio of -0.41 and a beta of -0.07. IN8bio has a twelve month low of $0.22 and a twelve month high of $2.48.

IN8bio (NASDAQ:INAB) last announced its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, research analysts predict that IN8bio will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp increased its holdings in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the period. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.